内容概要：随着国民健康意识不断提升、全民"减糖、控糖"意识深化，无糖/低糖食品饮料成为主流选 择，甜菊糖苷天然、低热量、不影响血糖的特性契合这一核心诉求，成为蔗糖及人工代糖的优选替代 品，与此同时，"健康中国"战略、食品添加剂标准优化及减糖相关政策，推动食品饮料企业主动使用天 然甜味剂，加之近年来，我国对甜菊糖苷的生产、提纯及应用标准逐步与国际接轨，企业合规成本逐步 降低，助力甜菊糖苷进入更广泛的终端领域，带动甜菊糖苷市场需求进一步扩大，据统计，2024年我国 甜菊糖苷行业市场规模达10.37亿元，同比增长10.2%。 相关上市企业：莱茵生物（002166）、晨光生物（300138）、三元生物（301206）、奔月生物 （873255.NQ） 相关企业：诸城市浩天药业有限公司、山东圣香远生物科技股份有限公司、曲阜圣仁制药有限公司、山 东华仙甜菊股份有限公司、曲阜绿田源高科有限公司、济宁奥星甜菊制品有限公司、谱赛科（江西）生 物技术有限公司、浙江绿世界制药有限公司、山东海根生物技术有限公司、蚌埠市华东生物科技有限公 司 关键词：甜菊糖苷行业发展历程、甜菊糖苷市场政策、甜菊糖苷产业链图谱、甜菊糖苷市场规模、甜菊 ...

Core Insights - The article discusses the transformative potential of biomanufacturing, which utilizes microorganisms to create sustainable products, thereby reducing reliance on fossil fuels and minimizing environmental impact [1][2][4]. Group 1: Biomanufacturing Overview - Biomanufacturing is defined as a process where microorganisms convert renewable resources into valuable products, such as biodegradable plastics and high-performance materials [2][3]. - The shift from traditional petrochemical-based production to biomanufacturing is seen as essential for achieving a more sustainable industrial model [2][4]. Group 2: Economic Impact and Market Potential - The biomanufacturing industry in China is approaching a total scale of nearly 1 trillion yuan, driven by policy support and capital investment [6]. - Utilizing agricultural waste, such as crop straw, could potentially generate over 1 million tons of biodegradable plastic annually, creating a market worth hundreds of billions [5][6]. Group 3: Industry Development and Collaboration - Companies like Kasei Biotech are forming strategic partnerships to develop biobased materials, demonstrating a collaborative approach to building a competitive biomanufacturing ecosystem [7]. - The integration of biomanufacturing in various sectors, including healthcare and consumer products, is expanding, with companies innovating in areas like biodegradable medical materials and low-sugar food products [8]. Group 4: Challenges and Barriers - The biomanufacturing sector faces challenges in scaling up from laboratory to industrial production, particularly in optimizing microbial strains and production processes [9][10]. - Regulatory hurdles and slow approval processes for genetically engineered strains hinder the speed of innovation and market entry for new biomanufactured products [9][10].

Summary of the Conference Call for Morning Bio Company Overview - **Company**: Morning Bio (晨光生物) - **Industry**: Natural colorants and health products Key Points and Arguments Industry Trends - The price of products such as chili red and chili extract is expected to rebound, indicating the end of the industry's price decline trend, with a clear turning point identified [2][4] - The demand for natural health products is continuously growing, with an increase in the penetration rate of natural colorants in mature markets and an expanding consumption share of natural medicinal extracts [2][8] - The U.S. is gradually phasing out synthetic colorants, which is expected to create significant incremental demand for natural colorants in the coming years [3][15] Financial Performance - In 2025, Morning Bio's overall operations have shown significant recovery, with improvements in revenue, product sales, and profits despite a decline in revenue due to lower product prices and accounting policy adjustments [4][26] - The company reported a profit of approximately 10 million yuan in Q3 2025, a significant improvement from a loss of nearly 100 million yuan in the same period last year [26] Product Insights - Lutein prices have increased by over ten percent due to a contraction in raw material supply, leading to a gradual recovery in gross margins [5][6] - Small varieties like stevia glycosides and Sichuan pepper extracts are showing good development trends, with strong demand anticipated [2][5] Cottonseed Business Strategy - Morning Bio is gradually developing its cottonseed business independently, focusing on processing rather than trading, with a current capacity of 1.1 million tons [2][7] - The company employs price locking and futures hedging to manage risks in the cottonseed business, ensuring stable profits [10][27] Market Position and Future Plans - The industry is characterized by high concentration, with few companies holding significant capacity, making additional capacity investments less meaningful [9][28] - Morning Bio aims to maintain stable processing operations and may consider a spin-off listing to attract industry partners [9][19] Cost Management and Inventory - The company uses a moving weighted average method for accounting, ensuring that inventory levels are managed effectively [11][12] - Safety stock is maintained to support several months of usage, with procurement strategies adjusted based on market conditions [12][25] Competitive Landscape - In the health food sector, Morning Bio primarily operates as an OEM, with over 70% of clients being overseas health product companies [22][20] - The company holds about one-third of the market share in lutein, with a competitive edge in raw material control and product quality [20][21] Financial Outlook - Management expenses are expected to grow in line with business development, while sales and financial expenses will grow at a slower rate than business growth due to scale effects [29] Regulatory Impact - The gradual elimination of synthetic colorants is expected to change the industry landscape, increasing technical barriers and potentially leading to price increases due to higher demand for natural colorants [28] Additional Important Insights - Morning Bio is actively expanding its health product offerings, including health foods and traditional Chinese medicine, with significant revenue growth anticipated from new production lines [19] - The company is also exploring overseas raw material sourcing, particularly in Zambia, although progress has been limited this year [14]

Core Viewpoint - Rhein Biotech is a leading company in the global plant extract industry, focusing on natural health products and possessing advanced extraction technology and a full industry chain advantage [1] Group 1: Business Performance - In Q3 2025, Rhein Biotech reported revenue of 1.272 billion yuan, ranking 12th in the industry, with the industry leader, Meihua Biological, generating 18.215 billion yuan [2] - The net profit for the same period was 79.1918 million yuan, placing the company 17th in the industry, while the top performer, New Hope Liuhe, achieved a net profit of 5.354 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Rhein Biotech's debt-to-asset ratio was 36.56%, higher than the industry average of 28.46%, indicating a relatively heavy debt burden [3] - The gross profit margin was 25.00%, lower than the industry average of 28.77%, suggesting a smaller profit space for the company's products [3] Group 3: Executive Compensation - The chairman and general manager, Xie Yongfu, received a salary of 938,000 yuan in 2024, an increase of 18,500 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.66% to 46,000, while the average number of circulating A-shares held per account increased by 31.16% to 16,000 [5] Group 5: Strategic Developments - Rhein Biotech aims to integrate "natural extraction + synthetic biology" as a strategic goal, having obtained multiple patents and launched a synthetic biology workshop [5] - The company has achieved mass production capability for steviol glycosides and is expected to receive FDA GRAS certification for left-handed β-glucan in 2025 [5] - Revenue forecasts for 2025-2027 are projected at 2.081 billion, 2.480 billion, and 2.996 billion yuan, with corresponding net profits of 213 million, 288 million, and 396 million yuan [5] Group 6: Market Outlook - According to Huaxin Securities, Rhein Biotech's revenue is expected to grow steadily in Q1 2025, although net profit margins may decline due to rising costs [6] - The company’s synthetic biology products have made significant progress, with FDA GRAS certification achieved for a synthetic steviol glycoside product [6]

Core Insights - The increasing health awareness among the public has led to a rise in demand for sugar-free and low-sugar diets, with a focus on identifying healthier sugar substitutes [1] Group 1: Research Findings - A review paper published by Associate Professor You Yilin and his team in the journal "Food Research International" systematically evaluated the impact of artificial and natural sweeteners on metabolic health, revealing that natural sweeteners outperform artificial ones in maintaining metabolic balance, regulating blood sugar, and improving gut health [2] - Natural sweeteners such as steviol glycosides, monk fruit extract, D-allulose, and erythritol exhibit milder metabolic pathways in the body, with erythritol being excreted by over 90% without participating in energy metabolism or causing blood sugar fluctuations [2] - Steviol glycosides and monk fruit extract can be metabolized by gut microbiota to produce secondary glycosides, which help improve insulin sensitivity, while D-allulose can reduce food intake and inhibit fat generation, showcasing unique advantages in weight control and metabolic burden reduction [2] Group 2: Molecular Mechanisms - At the molecular level, natural sweeteners not only provide taste satisfaction through sweet taste receptors but also activate the AMPK pathway, promoting fat breakdown and energy expenditure, indicating that the right choice of sweetener can potentially improve metabolic status and help prevent chronic diseases such as obesity and diabetes [2] - Erythritol, being naturally sourced from foods like corn, grapes, pears, and watermelon, has a refreshing taste, nearly zero calories, and minimal interference with gut microbiota, making it widely used in sugar-free beverages, gum, children's food, and nutritional supplements [4] Group 3: Industry Implications - The latest rankings of healthy sweeteners suggest that erythritol is likely to become a key direction for the future transformation of zero-sugar products in the beverage and food industry, as many pharmaceutical formulations are also beginning to replace sucrose with erythritol to reduce dental damage and blood sugar fluctuation risks [4]

Investment Rating - The investment rating for the company is maintained at "Outperform" [1] Core Insights - The company's performance aligns with expectations, with continuous optimization in the plant extraction business. The revenue for the first three quarters of 2025 was 5.05 billion yuan, a year-on-year decrease of 3.41%, while the net profit attributable to the parent company was 304 million yuan, a significant increase of 385.3% [7] - The report predicts net profits for 2025-2027 to be 324 million, 408 million, and 512 million yuan respectively, with year-on-year growth rates of 244.3%, 25.9%, and 25.7% [7] Financial Data and Profit Forecast - Total revenue for 2025 is estimated at 7.166 billion yuan, with a year-on-year growth rate of 2.5% [6] - The gross profit margin for Q3 2025 was 16.1%, an increase of 10.6 percentage points year-on-year [7] - The company’s net profit margin for Q3 2025 was 6.39%, up by 8.54 percentage points year-on-year [7] Business Performance - The plant extraction business generated revenue of 766 million yuan in Q3 2025, a year-on-year increase of 2.82%, while the cottonseed business revenue was 588 million yuan, a decrease of 34.6% [7] - The company has seen significant growth in sales of various products, including a 36% increase in chili red and an 87% increase in chili essence sales [7] Market Position and Strategy - The company is actively adjusting its cottonseed business and has completed inventory reserves to enhance pricing and market share advantages [7] - The report highlights that the company is in a price cycle bottom for its main plant extraction business, with expectations for continued performance recovery as prices gradually rise [7]

Market Overview - In September 2025, the domestic retail sales (社零) totaled 4.20 trillion yuan, with a year-on-year growth of 3.0%, slightly below market expectations [6][4] - Cumulative retail sales from January to September 2025 reached 36.59 trillion yuan, reflecting a year-on-year increase of 4.5% [6] - Online retail channels continued to outperform the overall retail market, with physical goods online retail sales growing by 6.5% year-on-year [6] Apparel and Textile Industry - The textile and apparel retail sales in September 2025 showed marginal improvement, with a cumulative year-on-year growth of 3.1% from January to September [5] - The sports and entertainment goods segment experienced faster growth, with a cumulative year-on-year increase of 19.6% and a monthly growth of 11.9% in September [5] - Companies like 361 Degrees and Xtep International reported healthy growth in retail sales, with 361 Degrees leveraging high-quality products and rapid expansion of super stores [5][12] Cosmetics and Jewelry Sector - The cosmetics sector saw a year-on-year growth of 8.6% in September, with a month-on-month increase of 3.5 percentage points [6] - The gold and jewelry retail sales grew by 9.7% year-on-year, although demand was temporarily suppressed by rising gold prices [6][8] - The performance of brands like Lao Pu Gold during the "Double 11" shopping festival was exceptionally strong, achieving record sales [8][12] Export Performance - From January to September 2025, China's textile and apparel exports amounted to 106.48 billion USD and 115.21 billion USD respectively, with year-on-year growth rates of 2.1% and a decline of 2.5% [9][12] - Vietnam's textile and apparel exports showed a cumulative year-on-year growth of 8.77%, indicating a competitive edge in the region [9][12] Company-Specific Insights - Morning Light Bio (晨光生物) is expected to report a net profit of 278 million to 314 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 344.05% to 401.55% [13][15] - The company is positioned to benefit from the FDA's new policies promoting natural colorants, with the global natural colorant market projected to double from 2.1 billion USD to 4.2 billion USD [13][14] - Morning Light Bio's key products, such as chili red and lutein, are leading in the global market, enhancing its competitive position [13][15]

Summary of the Conference Call for Morning Bio Industry Overview - The industry is experiencing a recovery in supply-demand dynamics, with a decrease in raw material planting areas and a continuous increase in demand. The trend towards natural product substitution is evident, leading to a forecasted moderate recovery in industry profitability over the next few years [2][7]. Company Performance - In the first three quarters of 2025, Morning Bio's main products, including chili red and chili extract, saw steady sales growth and significant improvement in gross margins. The overall operational trend is similar to the first half of the year [2]. - The company achieved a net profit of between 63 million and 99 million in the third quarter, marking a return to profitability due to increased revenue and gross margins from direct sales products and a recovery in the cottonseed business [4]. - Various products reached historical sales highs, although there remains a gap compared to the peaks of 2022-2023, primarily due to some products being at historical low prices and industry capacity recovery [6]. Product Insights - Chili red sales grew by 40% year-on-year in the first half of 2025, with an expected annual growth rate stabilizing around 20%. The company anticipates maintaining a compound annual growth rate of about 10% in the long term [10]. - The chili extract's gross margin is currently around 20%, with optimistic expectations for raw material price increases, which could significantly improve product profitability [11]. - The company has expanded its health food production capacity with a new facility that adds 1 billion units, expected to generate revenue of 220 million to 300 million in 2026 [3][21]. Strategic Initiatives - To address potential raw material supply tightness, the company has taken proactive measures, including reserving low-cost raw materials and expanding overseas sourcing in regions like Africa, India, and Myanmar [8]. - The company is also focusing on technological reserves to meet downstream demand, including the development of water-soluble pigments and customized application products [9]. Market Position and Future Outlook - The market share for chili red is projected to increase to over 50% in 2025, with a mid-term goal of over 80%. The industry is expected to return to a natural growth rate of 10-20% in the coming years [2][20]. - The cottonseed business is expected to maintain stable revenue and profitability, with a net profit of at least 5,000 to 6,000 per ton, indicating a favorable outlook for the next year [20]. - The health food sector is viewed as a continuously developing and rapidly growing market, with Morning Bio aiming to provide high-quality raw materials and products while creating long-term profits for shareholders [23]. Additional Insights - The company has seen a significant increase in sales of other products, such as tomato lycopene and stevia, with sales growth of approximately 50% in the first half of 2025 [17]. - The company is also exploring self-branded products and expanding its market presence through various sales channels, including online platforms [22]. This summary encapsulates the key points from the conference call, highlighting the company's performance, strategic initiatives, and future outlook within the industry.

Core Viewpoint - The article highlights the investment in Sichuan Yingjiaohesheng Technology Co., Ltd., a major producer of steviol glycosides, emphasizing its innovative approach using synthetic biology and its significant market potential in the sugar substitute industry [5][8]. Group 1: Company Overview - Yingjiaohesheng was established in 2015 and focuses on producing natural products using synthetic biology technology, with applications in pharmaceuticals, health supplements, and food and beverages [8]. - The company is recognized as one of the largest suppliers of steviol glycosides in China and has successfully entered the U.S. market since 2019, becoming part of the global supply chains of several international food and beverage companies [8][10]. - Yingjiaohesheng's product line includes coenzyme Q10, new steviol glycosides, β-nicotinamide mononucleotide (NMN), and vanillin, covering multiple sectors [8]. Group 2: Market and Technology - Steviol glycosides are a key component in many "zero-calorie" food and beverage products, with a caloric value only 1/300 that of sucrose, making them a popular sugar substitute [6][8]. - The company’s unique technology route—synthetic biology—offers significant cost advantages over traditional extraction methods, which have low yield and high waste [10]. - Synthetic biology allows for the production of steviol glycosides at a scale that can surpass traditional methods, with one fermentation tank yielding the equivalent of thousands of acres of stevia plants [10]. Group 3: Industry Context and Policy Support - The synthetic biology sector in China has seen increased investment and policy support, with total annual investments ranging from 50 to 100 billion RMB from 2018 to 2020, and a significant surge in 2021 [14][15]. - Chengdu, where Yingjiaohesheng is located, has strategically positioned itself as a hub for the biopharmaceutical industry, with a total scale of 350 billion RMB in the health industry as of 2023 [19][20]. - The city has implemented policies to foster the development of synthetic biology, aiming to create a robust ecosystem that integrates innovation, capital, and industry [21][22].

Core Viewpoint - The article highlights the investment in Sichuan Yingjia Hesheng Technology Co., Ltd., a major producer of steviol glycosides, emphasizing its role in the synthetic biology sector and its potential for growth in various markets, particularly in the U.S. and Southeast Asia [2][5]. Company Overview - Yingjia Hesheng, established in 2015, focuses on using synthetic biology to manufacture natural products, with applications in pharmaceuticals, health care, and food and beverage industries [4]. - It is the largest supplier of steviol glycosides in China and one of only three companies globally to receive GRAS certification for its rare steviol glycoside, Rebaudioside I [3][5]. Market Position - Since 2019, Yingjia Hesheng has successfully entered the U.S. market and is part of the supply chains of several international food and beverage companies, with increasing sales in the UK and Southeast Asia [5]. - The company is also planning to expand into emerging markets such as Japan and South Korea [5]. Product Line - In addition to steviol glycosides, Yingjia Hesheng's product portfolio includes Coenzyme Q10, new types of steviol glycosides, β-Nicotinamide Mononucleotide (NMN), and vanillin, covering multiple sectors including pharmaceuticals and health supplements [5]. Industry Development - Chengdu is positioning itself as a significant hub for synthetic biology and biomanufacturing, with over 300 biopharmaceutical projects introduced by the end of 2024, and a total industry scale exceeding 350 billion yuan [9][10]. - The local government has implemented policies to support the development of synthetic biology, recognizing its potential to replace traditional chemical processes and enhance the local economy [10][11].